RxDoctor Payments Data

Steven Mays, MD

Dermatology · Houston, TXNPI 1942240031

Payments from drug & device makers

$1,775in general payments, 2019–2025

Across 93 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$625
  • Sanofi$210
  • LEO Pharma Inc.$204
  • Novartis$155
  • Pfizer$145
  • Amgen$129
  • plus $308 from 8 others

What the payments were for

  • Food & beverage$1,69796%
  • Education$784%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,775 in reported general payments places this provider in the 30th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$115,252
Medicare patients
507
Services billed
1,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Unoready PenSecukinumab23$229,110
Taltz AutoinjectorIxekizumab20$166,799
EnbrelEtanercept22$157,650
RinvoqUpadacitinib13$84,956
Dupixent SyringeDupilumab12$45,393
Dupixent PenDupilumab11$38,817
Ivermectin14$7,048
Mycophenolate Mofetil15$3,983
Dapsone51$2,973
Triamcinolone Acetonide154$2,311
Minocycline Hcl50$2,144
Tacrolimus15$1,969
Azelaic Acid15$1,902
Doxycycline Monohydrate71$1,705
Ketoconazole72$1,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$129$157,65022 claims
AbbVieRinvoq$625$84,95613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →